Aurinia Pharmaceuticals AUPH Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $298.21M+648% | $287.2M+4,893% | $77.84M+445% | $60.64M+220% | $39.85M+164% | ||
| $19.41M-0.2% | $19.45M0.0% | $19.45M-0.4% | $19.48M-2.1% | $19.45M+23.3% | ||
| $17.22M-23.3% | $14.68M-53.5% | $16.9M-50.9% | $19.3M-49.1% | $22.45M-46.0% | ||
| $166.92M+160% | $135.66M+206% | $120.1M— | $92.68M— | $64.29M— | ||
| —— | —— | —— | —— | —— | ||
| $87.4M+16.8% | $98.16M+144% | $119.96M+551% | $111.29M+504% | $74.86M+509% | ||
| -$110.46M-32.5% | -$106.11M-116% | -$127.27M-302% | -$119.5M-283% | -$83.38M-282% | ||
| —— | —— | —— | $19.6M+139% | $1.97M+107% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Aurinia Pharmaceuticals's cash flow data come from?
- Every line is extracted from Aurinia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.